Sanofi SNY · Stock Open Sanofi in new tab
Sanofi Analysis (SNY)
Is Sanofi a good investment? Sanofi (SNY) is currently trading at 43.16 USD. Market analysts have a consensus price target of 55.90 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 19.09. This valuation is generally in line with the broader market.
Earnings Schedule: Sanofi is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is 5.29.
For income investors, Sanofi pays a dividend yield of 5.64%. With a payout ratio of 46%, the dividend appears sustainable.
Investor FAQ
Does Sanofi pay a dividend?
Yes, it pays an annual dividend of 4.12 USD (5.64% yield).
What asset class is Sanofi?
Sanofi is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of 2.25.
Company Profile
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
| Year | Total Dividends |
|---|---|
| ▸2027 |
2.59 USD
|
| June 2, 2027 (estimated) | 2.5925 |
| ▸2026 |
2.42 USD
|
| June 3, 2026 | 2.4220 |
| ▸2025 |
2.21 USD
|
| June 12, 2025 | 2.2120 |
| ▸2024 |
2.04 USD
|
| June 6, 2024 | 2.0370 |
| ▸2023 |
1.90 USD
|
| June 23, 2023 | 1.9030 |
| ▸2022 |
2.04 USD
|
| June 27, 2022 | 0.2970 |
| May 31, 2022 | 1.7470 |
| ▸2021 |
1.91 USD
|
| May 26, 2021 | 1.9060 |
| ▸2020 |
1.75 USD
|
| May 26, 2020 | 1.7530 |
| ▸2019 |
1.74 USD
|
| May 31, 2019 | 1.7390 |
| ▸2018 |
1.86 USD
|
| June 4, 2018 | 1.8610 |
| ▸2017 |
1.58 USD
|
| June 7, 2017 | 1.5770 |
| ▸2016 |
1.63 USD
|
| June 1, 2016 | 1.6300 |
| ▸2015 |
1.62 USD
|
| June 2, 2015 | 1.6180 |
| ▸2014 |
1.91 USD
|
| June 5, 2014 | 1.9100 |
| ▸2013 |
1.86 USD
|
| June 5, 2013 | 1.8620 |
| ▸2012 |
1.76 USD
|
| May 30, 2012 | 1.7560 |
| ▸2011 |
1.82 USD
|
| June 24, 2011 | 1.8220 |
| ▸2010 |
1.63 USD
|
| May 17, 2010 | 1.6270 |
| ▸2009 |
1.42 USD
|
| April 20, 2009 | 1.4190 |
| ▸2008 |
1.51 USD
|
| May 16, 2008 | 1.5100 |
| ▸2007 |
1.15 USD
|
| June 4, 2007 | 1.1450 |
| ▸2006 |
0.91 USD
|
| June 2, 2006 | 0.9120 |
| ▸2005 |
0.80 USD
|
| June 2, 2005 | 0.7990 |
| ▸2004 |
0.61 USD
|
| Sept. 27, 2004 | 0.0300 |
| April 30, 2004 | 0.5800 |
| ▸2003 |
0.46 USD
|
| May 28, 2003 | 0.4620 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Sanofi | Jun 03, 2026 | Paid | 2.422 USD |
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 30, 2013 | 5.000000 |
| Nov. 17, 2010 | 10.000000 |
Community Discussion